Skip to content

Clinical trials

Terminated Myelodysplastic Syndromes trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelodysplastic Syndromes Status: Terminated Country / region: United States Clear all

258 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20014
20023
20031
20049
20059
200617
200719
200820
200915
201010
201112
20127
20139
201410
201514
201615
201717
201811
20198
20209
202115
202210
20235
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated258

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center28
Masonic Cancer Center, University of Minnesota17
Fred Hutchinson Cancer Center12
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins7
Celgene5
Incyte Corporation5
National Cancer Institute (NCI)5
Novartis Pharmaceuticals5
OHSU Knight Cancer Institute5
Massachusetts General Hospital4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelodysplastic Syndromes258
Leukemia, Myeloid, Acute144
Leukemia100
Precursor Cell Lymphoblastic Leukemia-Lymphoma81
Multiple Myeloma64
Leukemia, Myelomonocytic, Chronic57
Lymphoma54
Leukemia, Lymphocytic, Chronic, B-Cell53
Lymphoma, Non-Hodgkin50
Hodgkin Disease44

Trials

Showing 1 to 25 of 258. Each trial links to its page on Pharma Observatory.

158 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.